Sarepta

Read more
Douglas S. Ingram's photo - President & CEO of Sarepta

President & CEO

Douglas S. Ingram

CEO Approval Rating

84/100

Founded:

1980

Status:

PublicIndependent CompanyNASDAQSRPT

SAREPTA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Moderna is Sarepta's biggest rival. Moderna was founded in 2010, and is headquartered in Cambridge, Massachusetts. Moderna competes in the Biotechnology industry. Moderna generates $2.2B more revenue vs. Sarepta.

Alnylam is one of Sarepta's top competitors. Alnylam's headquarters is in Cambridge, Massachusetts, and was founded in 2002. Like Sarepta, Alnylam also works within the Pharmaceuticals sector. Alnylam generates 99% of Sarepta's revenue.

Ionis is seen as one of Sarepta's top competitors. Ionis is a Public company that was founded in 1989 in Carlsbad, California. Like Sarepta, Ionis also works within the Pharmaceuticals sector. Compared to Sarepta, Ionis has 258 more employees.

Sarepta Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$573.4M

Sarepta's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 478.7M. Over the last four quarters, Sarepta's revenue has grown by 7%. Specifically, in Q1 2021's revenue was $146.9M; in Q4 2020, it was $145.1M; in Q3 2020, it was $143.9M; in Q2 2020, Sarepta's revenue was $137.4M.

Sarepta Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Myonexus Therapeutics, Inc.

Feb 2019

Source »
$165M
Myonexus develops gene therapies for the treatment of limb girdle muscular dystrophies.

-

-

Jul 2003

Source »
$11M
-

Sarepta Funding History

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Feb 2020
$400M
-
Debt
Dec 2019
$250M

Pharmakon Advisors, LP

Equity
Nov 2019
$30.5M
-
Debt
Jul 2017
$60M
Equity
Oct 2015
$126.8M

Sarepta Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

StrideBio is a North Carolina-based biotechnology firm that develops and commercializes gene therapies for the treatment of CNS and cardiovascular disorders.
$81.5M
Mar 15, 2021
Series B
-
AavantiBio is a biotechnology company that develops and commercializes gene therapies for the treatment of fatal diseases.
$107M
Oct 21, 2020
Series A
-
Lacerta is a clinical-stage gene therapy company that focuses on developing treatments for the central nervous system and lysosomal storage diseases.
$30M
Aug 12, 2018
Equity
-

Sarepta News

Sarepta Press Releases

Sarepta Videos

Social Media

Sarepta Headquarters

215 First Street

Cambridge, Massachusetts02142

617-274-4000

Driving Directions »

Trending Companies

Sarepta Summary

ABOUT

Overview

Sarepta develops and commercializes ribonucleic acid targeted therapeutics for the treatment of neuromuscular diseases. Sarepta was founded in 1980. Sarepta's headquarters is located in Cambridge, Massachusetts, USA 02142. It has raised 942.3M in 9 ro...

CEO

Sarepta's President & CEO, Douglas S. Ingram, currently has an approval rating of 84%. Sarepta's primary competitors are Moderna, Alnylam & Ionis.

Frequently Asked Questions about Sarepta

  1. When was Sarepta founded?

    Sarepta was founded in 1980
  2. Who is Sarepta's CEO?

    Sarepta's CEO is Douglas S. Ingram
  3. How much revenue does Sarepta generate?

    Sarepta generates $573.4M in revenue
  4. How much funding does Sarepta have?

    Sarepta has historically raised $942.3M in funding
  5. Where is Sarepta's headquarters?

    Sarepta's headquarters is in Cambridge Massachusetts, USA
  1. How many employees does Sarepta have?

    Sarepta has 499 employees
  2. What sector does Sarepta operate in?

    Sarepta is in Pharmaceuticals
  3. Who are Sarepta's competitors?

    Sarepta's top competitors are Moderna, Alnylam, Ionis
  4. Who has Sarepta invested in?

    Sarepta's has invested in companies such as StrideBio, AavantiBio, Lacerta Therapeutics